Your Followed Topics

86.56%
health2h ago

Key facts: EMA backs AstraZeneca camizestrant; SERENA-6 reports PFS2

Key facts: EMA backs AstraZeneca camizestrant; SERENA-6 reports PFS2 Open in Tradingview.com
Highlights
  • EMA gives positive opinion on AstraZeneca camizestrant, sending decision to the European Commission for final authorization.
  • SERENA-6 results show camizestrant with CDK4/6 inhibitors in first-line HR+/HER2– disease with ESR1 mutation, including final PFS2 data.
  • Final PFS2 and ctDNA clearance data were part of the SERENA-6 findings.

Virality Score Timeline

Vote 0
0

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 587 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement